nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Ifosfamide—testicular cancer	0.128	0.412	CbGbCtD
Trametinib—CYP2C8—Etoposide—testicular cancer	0.0612	0.197	CbGbCtD
Trametinib—CYP3A4—Ifosfamide—testicular cancer	0.052	0.167	CbGbCtD
Trametinib—CYP3A4—Vinblastine—testicular cancer	0.0276	0.0887	CbGbCtD
Trametinib—CYP3A4—Etoposide—testicular cancer	0.0248	0.0799	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—testicular cancer	0.0169	0.0545	CbGbCtD
Trametinib—MAP2K1—embryo—testicular cancer	0.0115	0.17	CbGeAlD
Trametinib—MAP2K2—seminal vesicle—testicular cancer	0.00951	0.141	CbGeAlD
Trametinib—MAP2K1—gonad—testicular cancer	0.00781	0.115	CbGeAlD
Trametinib—MAP2K2—gonad—testicular cancer	0.00688	0.102	CbGeAlD
Trametinib—MAP2K1—female gonad—testicular cancer	0.00635	0.0939	CbGeAlD
Trametinib—MAP2K1—testis—testicular cancer	0.00563	0.0832	CbGeAlD
Trametinib—MAP2K2—female gonad—testicular cancer	0.00559	0.0826	CbGeAlD
Trametinib—MAP2K2—testis—testicular cancer	0.00496	0.0733	CbGeAlD
Trametinib—MAP2K1—lymph node—testicular cancer	0.00408	0.0603	CbGeAlD
Trametinib—MAP2K1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00372	0.0225	CbGpPWpGaD
Trametinib—MAP2K2—lymph node—testicular cancer	0.00359	0.0531	CbGeAlD
Trametinib—MAP2K1—BCR signaling pathway—BCL10—testicular cancer	0.00307	0.0186	CbGpPWpGaD
Trametinib—MAP2K2—Bladder Cancer—FGFR3—testicular cancer	0.00273	0.0165	CbGpPWpGaD
Trametinib—MAP2K2—TCR Signaling Pathway—BCL10—testicular cancer	0.00259	0.0157	CbGpPWpGaD
Trametinib—MAP2K1—Bladder Cancer—FGFR3—testicular cancer	0.00255	0.0154	CbGpPWpGaD
Trametinib—MAP2K2—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	0.00246	0.0149	CbGpPWpGaD
Trametinib—MAP2K2—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.00244	0.0148	CbGpPWpGaD
Trametinib—MAP2K1—TCR Signaling Pathway—BCL10—testicular cancer	0.00243	0.0147	CbGpPWpGaD
Trametinib—MAP2K1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	0.0023	0.0139	CbGpPWpGaD
Trametinib—MAP2K1—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.00229	0.0138	CbGpPWpGaD
Trametinib—MAP2K2—Kit receptor signaling pathway—KITLG—testicular cancer	0.00219	0.0133	CbGpPWpGaD
Trametinib—MAP2K2—FRS2-mediated cascade—FGFR3—testicular cancer	0.00206	0.0125	CbGpPWpGaD
Trametinib—MAP2K1—Kit receptor signaling pathway—KITLG—testicular cancer	0.00205	0.0124	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—PRDM14—testicular cancer	0.00201	0.0122	CbGpPWpGaD
Trametinib—MAP2K1—FRS2-mediated cascade—FGFR3—testicular cancer	0.00193	0.0117	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—PRDM14—testicular cancer	0.00188	0.0114	CbGpPWpGaD
Trametinib—MAP2K2—IRS-mediated signalling—STK11—testicular cancer	0.00177	0.0107	CbGpPWpGaD
Trametinib—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00175	0.0106	CbGpPWpGaD
Trametinib—MAP2K2—IRS-related events—STK11—testicular cancer	0.00172	0.0104	CbGpPWpGaD
Trametinib—CYP2C8—testis—testicular cancer	0.00172	0.0254	CbGeAlD
Trametinib—MAP2K2—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.00171	0.0103	CbGpPWpGaD
Trametinib—MAP2K2—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	0.00168	0.0102	CbGpPWpGaD
Trametinib—MAP2K2—IGF1R signaling cascade—STK11—testicular cancer	0.00166	0.01	CbGpPWpGaD
Trametinib—MAP2K2—Insulin receptor signalling cascade—STK11—testicular cancer	0.00166	0.01	CbGpPWpGaD
Trametinib—MAP2K1—IRS-mediated signalling—STK11—testicular cancer	0.00166	0.01	CbGpPWpGaD
Trametinib—MAP2K1—FOXM1 transcription factor network—MMP2—testicular cancer	0.00163	0.00984	CbGpPWpGaD
Trametinib—MAP2K1—IRS-related events—STK11—testicular cancer	0.00161	0.00973	CbGpPWpGaD
Trametinib—MAP2K1—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.0016	0.00964	CbGpPWpGaD
Trametinib—MAP2K1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	0.00157	0.00951	CbGpPWpGaD
Trametinib—MAP2K1—IGF1R signaling cascade—STK11—testicular cancer	0.00155	0.00939	CbGpPWpGaD
Trametinib—MAP2K1—Insulin receptor signalling cascade—STK11—testicular cancer	0.00155	0.00939	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.00151	0.00913	CbGpPWpGaD
Trametinib—MAP2K2—Kit receptor signaling pathway—KIT—testicular cancer	0.0015	0.00904	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.00141	0.00854	CbGpPWpGaD
Trametinib—MAP2K1—Kit receptor signaling pathway—KIT—testicular cancer	0.0014	0.00846	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Insulin receptor—STK11—testicular cancer	0.00138	0.00834	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Insulin receptor—STK11—testicular cancer	0.00129	0.0078	CbGpPWpGaD
Trametinib—MAP2K2—IRS-mediated signalling—FGFR3—testicular cancer	0.00122	0.00735	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00119	0.00721	CbGpPWpGaD
Trametinib—MAP2K2—IRS-related events—FGFR3—testicular cancer	0.00118	0.00715	CbGpPWpGaD
Trametinib—MAP2K2—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.00117	0.00709	CbGpPWpGaD
Trametinib—MAP2K2—IGF1R signaling cascade—FGFR3—testicular cancer	0.00114	0.0069	CbGpPWpGaD
Trametinib—MAP2K2—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.00114	0.0069	CbGpPWpGaD
Trametinib—MAP2K1—IRS-mediated signalling—FGFR3—testicular cancer	0.00114	0.00688	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—MMP2—testicular cancer	0.00113	0.00685	CbGpPWpGaD
Trametinib—MAP2K1—IRS-related events—FGFR3—testicular cancer	0.00111	0.00669	CbGpPWpGaD
Trametinib—MAP2K1—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.0011	0.00663	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—KITLG—testicular cancer	0.00109	0.0066	CbGpPWpGaD
Trametinib—MAP2K1—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.00107	0.00646	CbGpPWpGaD
Trametinib—MAP2K1—IGF1R signaling cascade—FGFR3—testicular cancer	0.00107	0.00646	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.00104	0.00632	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—KITLG—testicular cancer	0.00103	0.00622	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—KITLG—testicular cancer	0.00102	0.00618	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—KITLG—testicular cancer	0.000982	0.00594	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000977	0.00591	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—KITLG—testicular cancer	0.000977	0.00591	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—KITLG—testicular cancer	0.000972	0.00588	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—KITLG—testicular cancer	0.000968	0.00585	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—KITLG—testicular cancer	0.000962	0.00582	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000949	0.00573	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—KITLG—testicular cancer	0.000919	0.00555	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—KITLG—testicular cancer	0.000914	0.00553	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—KITLG—testicular cancer	0.00091	0.0055	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.00091	0.0055	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—KITLG—testicular cancer	0.00091	0.0055	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—KITLG—testicular cancer	0.00091	0.0055	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—KITLG—testicular cancer	0.000905	0.00547	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—KITLG—testicular cancer	0.000902	0.00545	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000894	0.00541	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—KITLG—testicular cancer	0.00089	0.00538	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000888	0.00537	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000866	0.00524	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000852	0.00515	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—KITLG—testicular cancer	0.000852	0.00515	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—KITLG—testicular cancer	0.000852	0.00515	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—KITLG—testicular cancer	0.000844	0.0051	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000837	0.00506	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—KITLG—testicular cancer	0.000833	0.00503	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000811	0.00491	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000806	0.00487	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000776	0.00469	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000776	0.00469	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—INSL3—testicular cancer	0.000766	0.00463	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—FGFR3—testicular cancer	0.000764	0.00462	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000759	0.00459	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000754	0.00456	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—KIT—testicular cancer	0.000745	0.0045	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—FGFR3—testicular cancer	0.00073	0.00441	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000726	0.00439	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000726	0.00439	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—FGFR3—testicular cancer	0.000726	0.00439	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—FGFR3—testicular cancer	0.000723	0.00437	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—FGFR3—testicular cancer	0.000719	0.00435	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—INSL3—testicular cancer	0.000716	0.00433	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—FGFR3—testicular cancer	0.000715	0.00432	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000713	0.00431	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—KIT—testicular cancer	0.000702	0.00424	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—KIT—testicular cancer	0.000697	0.00421	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—FGFR3—testicular cancer	0.000683	0.00413	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—FGFR3—testicular cancer	0.000679	0.00411	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000677	0.00409	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000677	0.00409	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—FGFR3—testicular cancer	0.000677	0.00409	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—FGFR3—testicular cancer	0.000676	0.00409	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—FGFR3—testicular cancer	0.000673	0.00407	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—FGFR3—testicular cancer	0.00067	0.00405	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—KIT—testicular cancer	0.00067	0.00405	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000667	0.00403	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—KIT—testicular cancer	0.000667	0.00403	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000665	0.00402	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—KIT—testicular cancer	0.000663	0.00401	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—FGFR3—testicular cancer	0.000662	0.004	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—KIT—testicular cancer	0.00066	0.00399	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—KIT—testicular cancer	0.000656	0.00397	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—HPGDS—testicular cancer	0.000652	0.00394	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000633	0.00383	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000633	0.00383	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—FGFR3—testicular cancer	0.000633	0.00383	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—FGFR3—testicular cancer	0.000627	0.00379	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—KIT—testicular cancer	0.000627	0.00379	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—KIT—testicular cancer	0.000624	0.00377	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000622	0.00376	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—KIT—testicular cancer	0.000621	0.00375	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000621	0.00375	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—KIT—testicular cancer	0.000621	0.00375	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—KIT—testicular cancer	0.000621	0.00375	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—KITLG—testicular cancer	0.00062	0.00375	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—FGFR3—testicular cancer	0.000619	0.00374	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—KIT—testicular cancer	0.000618	0.00373	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—KIT—testicular cancer	0.000616	0.00372	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—KIT—testicular cancer	0.00061	0.00369	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—KIT—testicular cancer	0.000607	0.00367	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000599	0.00362	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—BCL10—testicular cancer	0.000587	0.00355	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—KIT—testicular cancer	0.000581	0.00351	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000581	0.00351	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—KIT—testicular cancer	0.000581	0.00351	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—KITLG—testicular cancer	0.00058	0.00351	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—KIT—testicular cancer	0.000576	0.00348	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000571	0.00345	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—KIT—testicular cancer	0.000568	0.00344	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000561	0.00339	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.00055	0.00333	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—BCL10—testicular cancer	0.000549	0.00332	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000515	0.00311	CbGpPWpGaD
Trametinib—Thrombocytopenia—Cisplatin—testicular cancer	0.000468	0.00102	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—testicular cancer	0.000467	0.00102	CcSEcCtD
Trametinib—Asthenia—Bleomycin—testicular cancer	0.000465	0.00102	CcSEcCtD
Trametinib—Dehydration—Epirubicin—testicular cancer	0.000464	0.00102	CcSEcCtD
Trametinib—Skin disorder—Cisplatin—testicular cancer	0.000464	0.00102	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—testicular cancer	0.000464	0.00102	CcSEcCtD
Trametinib—Hypertension—Etoposide—testicular cancer	0.000463	0.00101	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—testicular cancer	0.000462	0.00101	CcSEcCtD
Trametinib—Hyperhidrosis—Cisplatin—testicular cancer	0.000462	0.00101	CcSEcCtD
Trametinib—MAP2K2—Signaling by NGF—FGFR3—testicular cancer	0.000461	0.00279	CbGpPWpGaD
Trametinib—Pruritus—Bleomycin—testicular cancer	0.000459	0.00101	CcSEcCtD
Trametinib—Dry skin—Epirubicin—testicular cancer	0.000457	0.001	CcSEcCtD
Trametinib—Nausea—Vinblastine—testicular cancer	0.000456	0.000999	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—testicular cancer	0.000456	0.000999	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—testicular cancer	0.000454	0.000995	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000453	0.000993	CcSEcCtD
Trametinib—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000453	0.000993	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways—INSL3—testicular cancer	0.000452	0.00273	CbGpPWpGaD
Trametinib—Pancreatitis—Methotrexate—testicular cancer	0.000452	0.00099	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.000449	0.000985	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—testicular cancer	0.000442	0.000968	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00044	0.000965	CcSEcCtD
Trametinib—Abdominal pain—Ifosfamide—testicular cancer	0.000438	0.00096	CcSEcCtD
Trametinib—Body temperature increased—Ifosfamide—testicular cancer	0.000438	0.00096	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000435	0.000954	CcSEcCtD
Trametinib—Infection—Etoposide—testicular cancer	0.000435	0.000953	CcSEcCtD
Trametinib—Asthenia—Dactinomycin—testicular cancer	0.000434	0.000951	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—testicular cancer	0.000433	0.000948	CcSEcCtD
Trametinib—MAP2K1—Signaling by NGF—FGFR3—testicular cancer	0.000431	0.00261	CbGpPWpGaD
Trametinib—Neutropenia—Methotrexate—testicular cancer	0.000431	0.000944	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—testicular cancer	0.000429	0.000941	CcSEcCtD
Trametinib—Thrombocytopenia—Etoposide—testicular cancer	0.000428	0.000939	CcSEcCtD
Trametinib—Skin disorder—Etoposide—testicular cancer	0.000425	0.000931	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—testicular cancer	0.000423	0.000927	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—INSL3—testicular cancer	0.000423	0.00256	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—KIT—testicular cancer	0.000423	0.00256	CbGpPWpGaD
Trametinib—Hyperhidrosis—Etoposide—testicular cancer	0.000423	0.000927	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—testicular cancer	0.000423	0.000927	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—testicular cancer	0.000422	0.000924	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—testicular cancer	0.00042	0.000921	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000416	0.000911	CcSEcCtD
Trametinib—Decreased appetite—Cisplatin—testicular cancer	0.000415	0.00091	CcSEcCtD
Trametinib—Diarrhoea—Dactinomycin—testicular cancer	0.000414	0.000906	CcSEcCtD
Trametinib—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000412	0.000904	CcSEcCtD
Trametinib—Vomiting—Bleomycin—testicular cancer	0.000412	0.000903	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—testicular cancer	0.000411	0.000901	CcSEcCtD
Trametinib—Infestation—Methotrexate—testicular cancer	0.000411	0.000901	CcSEcCtD
Trametinib—Rash—Bleomycin—testicular cancer	0.000409	0.000896	CcSEcCtD
Trametinib—Dermatitis—Bleomycin—testicular cancer	0.000408	0.000895	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000407	0.000892	CcSEcCtD
Trametinib—Renal failure—Methotrexate—testicular cancer	0.000404	0.000885	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—testicular cancer	0.000403	0.000884	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—testicular cancer	0.000401	0.000878	CcSEcCtD
Trametinib—Asthenia—Ifosfamide—testicular cancer	0.000397	0.000871	CcSEcCtD
Trametinib—MAP2K1—Signaling by NGF—KIT—testicular cancer	0.000396	0.00239	CbGpPWpGaD
Trametinib—Pruritus—Ifosfamide—testicular cancer	0.000392	0.000859	CcSEcCtD
Trametinib—Haematuria—Methotrexate—testicular cancer	0.000392	0.000859	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—testicular cancer	0.000391	0.000857	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—testicular cancer	0.000389	0.000853	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—testicular cancer	0.000388	0.000849	CcSEcCtD
Trametinib—Nausea—Bleomycin—testicular cancer	0.000385	0.000844	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—testicular cancer	0.000385	0.000843	CcSEcCtD
Trametinib—Infestation—Epirubicin—testicular cancer	0.000385	0.000843	CcSEcCtD
Trametinib—Vomiting—Dactinomycin—testicular cancer	0.000384	0.000842	CcSEcCtD
Trametinib—Rash—Dactinomycin—testicular cancer	0.000381	0.000835	CcSEcCtD
Trametinib—Decreased appetite—Etoposide—testicular cancer	0.00038	0.000834	CcSEcCtD
Trametinib—Diarrhoea—Ifosfamide—testicular cancer	0.000379	0.000831	CcSEcCtD
Trametinib—Renal failure—Epirubicin—testicular cancer	0.000378	0.000828	CcSEcCtD
Trametinib—Gastrointestinal disorder—Etoposide—testicular cancer	0.000378	0.000828	CcSEcCtD
Trametinib—Body temperature increased—Cisplatin—testicular cancer	0.000378	0.000827	CcSEcCtD
Trametinib—Fatigue—Etoposide—testicular cancer	0.000377	0.000827	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—testicular cancer	0.000375	0.000821	CcSEcCtD
Trametinib—Constipation—Etoposide—testicular cancer	0.000374	0.00082	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—testicular cancer	0.000374	0.000819	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—testicular cancer	0.000373	0.000818	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—testicular cancer	0.000371	0.000813	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—testicular cancer	0.000369	0.000808	CcSEcCtD
Trametinib—Haematuria—Epirubicin—testicular cancer	0.000367	0.000804	CcSEcCtD
Trametinib—Dizziness—Ifosfamide—testicular cancer	0.000366	0.000803	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—testicular cancer	0.000364	0.000798	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—testicular cancer	0.000363	0.000795	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—testicular cancer	0.000362	0.000792	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—testicular cancer	0.00036	0.000789	CcSEcCtD
Trametinib—Nausea—Dactinomycin—testicular cancer	0.000359	0.000787	CcSEcCtD
Trametinib—Gastrointestinal pain—Etoposide—testicular cancer	0.000358	0.000784	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—testicular cancer	0.000356	0.00078	CcSEcCtD
Trametinib—Infestation—Doxorubicin—testicular cancer	0.000356	0.00078	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—KITLG—testicular cancer	0.000354	0.00214	CbGpPWpGaD
Trametinib—Vomiting—Ifosfamide—testicular cancer	0.000352	0.000772	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—testicular cancer	0.000351	0.00077	CcSEcCtD
Trametinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.00035	0.00212	CbGpPWpGaD
Trametinib—Renal failure—Doxorubicin—testicular cancer	0.00035	0.000767	CcSEcCtD
Trametinib—Rash—Ifosfamide—testicular cancer	0.000349	0.000765	CcSEcCtD
Trametinib—Dermatitis—Ifosfamide—testicular cancer	0.000349	0.000765	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—testicular cancer	0.000347	0.00076	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—testicular cancer	0.000347	0.00076	CcSEcCtD
Trametinib—Abdominal pain—Etoposide—testicular cancer	0.000346	0.000758	CcSEcCtD
Trametinib—Body temperature increased—Etoposide—testicular cancer	0.000346	0.000758	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—testicular cancer	0.000346	0.000758	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—testicular cancer	0.000345	0.000757	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—testicular cancer	0.000345	0.000755	CcSEcCtD
Trametinib—Asthenia—Cisplatin—testicular cancer	0.000343	0.000751	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—testicular cancer	0.000342	0.00075	CcSEcCtD
Trametinib—MAP2K2—Immune System—BCL10—testicular cancer	0.000342	0.00207	CbGpPWpGaD
Trametinib—Urinary tract disorder—Epirubicin—testicular cancer	0.000341	0.000747	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—testicular cancer	0.00034	0.000745	CcSEcCtD
Trametinib—MAP2K2—Axon guidance—MMP2—testicular cancer	0.000339	0.00205	CbGpPWpGaD
Trametinib—Haematuria—Doxorubicin—testicular cancer	0.000339	0.000743	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—testicular cancer	0.000339	0.000743	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—testicular cancer	0.000338	0.000742	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—testicular cancer	0.000336	0.000735	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—testicular cancer	0.000335	0.000733	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—testicular cancer	0.000332	0.000729	CcSEcCtD
Trametinib—Chills—Methotrexate—testicular cancer	0.000331	0.000725	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—KITLG—testicular cancer	0.000331	0.002	CbGpPWpGaD
Trametinib—Nausea—Ifosfamide—testicular cancer	0.000329	0.000721	CcSEcCtD
Trametinib—Diarrhoea—Cisplatin—testicular cancer	0.000327	0.000716	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—testicular cancer	0.000325	0.000713	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—testicular cancer	0.000323	0.000708	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—testicular cancer	0.000323	0.000707	CcSEcCtD
Trametinib—Erythema—Methotrexate—testicular cancer	0.000321	0.000704	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—testicular cancer	0.000321	0.000704	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—testicular cancer	0.000321	0.000704	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—testicular cancer	0.00032	0.000702	CcSEcCtD
Trametinib—MAP2K1—Immune System—BCL10—testicular cancer	0.00032	0.00193	CbGpPWpGaD
Trametinib—Haemorrhage—Doxorubicin—testicular cancer	0.000319	0.0007	CcSEcCtD
Trametinib—MAP2K1—Axon guidance—MMP2—testicular cancer	0.000317	0.00192	CbGpPWpGaD
Trametinib—Urinary tract disorder—Doxorubicin—testicular cancer	0.000315	0.000691	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—testicular cancer	0.000315	0.00069	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—testicular cancer	0.000314	0.000689	CcSEcCtD
Trametinib—Asthenia—Etoposide—testicular cancer	0.000314	0.000688	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—testicular cancer	0.000314	0.000688	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—testicular cancer	0.000313	0.000686	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—testicular cancer	0.000313	0.000686	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—testicular cancer	0.000311	0.000682	CcSEcCtD
Trametinib—Back pain—Methotrexate—testicular cancer	0.000311	0.000681	CcSEcCtD
Trametinib—Chills—Epirubicin—testicular cancer	0.00031	0.000679	CcSEcCtD
Trametinib—Pruritus—Etoposide—testicular cancer	0.00031	0.000678	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—testicular cancer	0.000308	0.000676	CcSEcCtD
Trametinib—Vomiting—Cisplatin—testicular cancer	0.000304	0.000665	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—testicular cancer	0.000303	0.000663	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—testicular cancer	0.000302	0.000663	CcSEcCtD
Trametinib—Rash—Cisplatin—testicular cancer	0.000301	0.00066	CcSEcCtD
Trametinib—Dermatitis—Cisplatin—testicular cancer	0.000301	0.000659	CcSEcCtD
Trametinib—Erythema—Epirubicin—testicular cancer	0.000301	0.000659	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—testicular cancer	0.000301	0.000659	CcSEcCtD
Trametinib—Diarrhoea—Etoposide—testicular cancer	0.000299	0.000656	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—testicular cancer	0.000299	0.000654	CcSEcCtD
Trametinib—Anaemia—Methotrexate—testicular cancer	0.000297	0.00065	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—testicular cancer	0.000296	0.00065	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—testicular cancer	0.000294	0.000645	CcSEcCtD
Trametinib—Back pain—Epirubicin—testicular cancer	0.000291	0.000637	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—testicular cancer	0.00029	0.000635	CcSEcCtD
Trametinib—Dizziness—Etoposide—testicular cancer	0.000289	0.000634	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—testicular cancer	0.000289	0.000633	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—testicular cancer	0.000288	0.000631	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—testicular cancer	0.000287	0.00063	CcSEcCtD
Trametinib—Chills—Doxorubicin—testicular cancer	0.000287	0.000628	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—testicular cancer	0.000285	0.000625	CcSEcCtD
Trametinib—Nausea—Cisplatin—testicular cancer	0.000284	0.000622	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—testicular cancer	0.000283	0.000621	CcSEcCtD
Trametinib—Cough—Methotrexate—testicular cancer	0.00028	0.000614	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—testicular cancer	0.00028	0.000613	CcSEcCtD
Trametinib—Vomiting—Etoposide—testicular cancer	0.000278	0.00061	CcSEcCtD
Trametinib—Erythema—Doxorubicin—testicular cancer	0.000278	0.000609	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—testicular cancer	0.000278	0.000609	CcSEcCtD
Trametinib—Anaemia—Epirubicin—testicular cancer	0.000278	0.000609	CcSEcCtD
Trametinib—Rash—Etoposide—testicular cancer	0.000276	0.000605	CcSEcCtD
Trametinib—Dermatitis—Etoposide—testicular cancer	0.000276	0.000604	CcSEcCtD
Trametinib—Headache—Etoposide—testicular cancer	0.000274	0.000601	CcSEcCtD
Trametinib—Myalgia—Methotrexate—testicular cancer	0.000273	0.000599	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—testicular cancer	0.000273	0.000599	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—testicular cancer	0.000272	0.000597	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000272	0.000595	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—testicular cancer	0.000269	0.00059	CcSEcCtD
Trametinib—Back pain—Doxorubicin—testicular cancer	0.000269	0.000589	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—testicular cancer	0.000267	0.000586	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—FGFR3—testicular cancer	0.000263	0.00159	CbGpPWpGaD
Trametinib—Cough—Epirubicin—testicular cancer	0.000262	0.000575	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—testicular cancer	0.000262	0.000574	CcSEcCtD
Trametinib—Infection—Methotrexate—testicular cancer	0.00026	0.000571	CcSEcCtD
Trametinib—Nausea—Etoposide—testicular cancer	0.00026	0.00057	CcSEcCtD
Trametinib—Hypertension—Epirubicin—testicular cancer	0.000259	0.000569	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—testicular cancer	0.000257	0.000563	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—testicular cancer	0.000257	0.000563	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—testicular cancer	0.000257	0.000562	CcSEcCtD
Trametinib—Myalgia—Epirubicin—testicular cancer	0.000256	0.000561	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—testicular cancer	0.000256	0.000561	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—testicular cancer	0.000255	0.000558	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000254	0.000557	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—testicular cancer	0.000253	0.000555	CcSEcCtD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.00025	0.00151	CbGpPWpGaD
Trametinib—Dry mouth—Epirubicin—testicular cancer	0.00025	0.000548	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—testicular cancer	0.000249	0.000545	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—FGFR3—testicular cancer	0.000246	0.00149	CbGpPWpGaD
Trametinib—Oedema—Epirubicin—testicular cancer	0.000245	0.000537	CcSEcCtD
Trametinib—Infection—Epirubicin—testicular cancer	0.000244	0.000534	CcSEcCtD
Trametinib—Cough—Doxorubicin—testicular cancer	0.000243	0.000532	CcSEcCtD
Trametinib—MAP2K2—Developmental Biology—MMP2—testicular cancer	0.000242	0.00146	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KIT—testicular cancer	0.000241	0.00146	CbGpPWpGaD
Trametinib—Nervous system disorder—Epirubicin—testicular cancer	0.000241	0.000527	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—testicular cancer	0.00024	0.000526	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—testicular cancer	0.00024	0.000526	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000239	0.000523	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—testicular cancer	0.000238	0.000522	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—testicular cancer	0.000237	0.00052	CcSEcCtD
Trametinib—Insomnia—Methotrexate—testicular cancer	0.000237	0.000519	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—testicular cancer	0.000237	0.000519	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—testicular cancer	0.000237	0.000519	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000235	0.000515	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—testicular cancer	0.000232	0.000507	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—testicular cancer	0.000228	0.000499	CcSEcCtD
Trametinib—Oedema—Doxorubicin—testicular cancer	0.000227	0.000497	CcSEcCtD
Trametinib—MAP2K1—Developmental Biology—MMP2—testicular cancer	0.000227	0.00137	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000226	0.000496	CcSEcCtD
Trametinib—Fatigue—Methotrexate—testicular cancer	0.000226	0.000495	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—KIT—testicular cancer	0.000226	0.00136	CbGpPWpGaD
Trametinib—Infection—Doxorubicin—testicular cancer	0.000225	0.000494	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000223	0.00049	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—testicular cancer	0.000223	0.000488	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—testicular cancer	0.000222	0.000487	CcSEcCtD
Trametinib—Insomnia—Epirubicin—testicular cancer	0.000222	0.000486	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—testicular cancer	0.00022	0.000483	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—testicular cancer	0.000219	0.000481	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—testicular cancer	0.000214	0.00047	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—testicular cancer	0.000213	0.000467	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000212	0.000464	CcSEcCtD
Trametinib—Fatigue—Epirubicin—testicular cancer	0.000211	0.000463	CcSEcCtD
Trametinib—Constipation—Epirubicin—testicular cancer	0.00021	0.00046	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—testicular cancer	0.000207	0.000454	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—testicular cancer	0.000207	0.000454	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000207	0.000453	CcSEcCtD
Trametinib—MAP2K2—Disease—H2AFZ—testicular cancer	0.000207	0.00125	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KITLG—testicular cancer	0.000206	0.00125	CbGpPWpGaD
Trametinib—Insomnia—Doxorubicin—testicular cancer	0.000205	0.00045	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—testicular cancer	0.000201	0.00044	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—testicular cancer	0.000197	0.000432	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000196	0.000429	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—testicular cancer	0.000196	0.000429	CcSEcCtD
Trametinib—Constipation—Doxorubicin—testicular cancer	0.000194	0.000425	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—testicular cancer	0.000194	0.000425	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—testicular cancer	0.000194	0.000425	CcSEcCtD
Trametinib—MAP2K1—Disease—H2AFZ—testicular cancer	0.000193	0.00117	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KITLG—testicular cancer	0.000193	0.00117	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KITLG—testicular cancer	0.00019	0.00115	CbGpPWpGaD
Trametinib—Asthenia—Methotrexate—testicular cancer	0.000188	0.000412	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000186	0.000407	CcSEcCtD
Trametinib—Pruritus—Methotrexate—testicular cancer	0.000185	0.000406	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—testicular cancer	0.000179	0.000393	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—testicular cancer	0.000179	0.000393	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—testicular cancer	0.000179	0.000393	CcSEcCtD
Trametinib—MAP2K1—Disease—KITLG—testicular cancer	0.000178	0.00108	CbGpPWpGaD
Trametinib—Asthenia—Epirubicin—testicular cancer	0.000176	0.000386	CcSEcCtD
Trametinib—Pruritus—Epirubicin—testicular cancer	0.000174	0.00038	CcSEcCtD
Trametinib—Dizziness—Methotrexate—testicular cancer	0.000173	0.00038	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—testicular cancer	0.000168	0.000368	CcSEcCtD
Trametinib—Vomiting—Methotrexate—testicular cancer	0.000167	0.000365	CcSEcCtD
Trametinib—Rash—Methotrexate—testicular cancer	0.000165	0.000362	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—testicular cancer	0.000165	0.000362	CcSEcCtD
Trametinib—Headache—Methotrexate—testicular cancer	0.000164	0.00036	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—testicular cancer	0.000163	0.000357	CcSEcCtD
Trametinib—Dizziness—Epirubicin—testicular cancer	0.000162	0.000355	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—testicular cancer	0.000161	0.000352	CcSEcCtD
Trametinib—Vomiting—Epirubicin—testicular cancer	0.000156	0.000342	CcSEcCtD
Trametinib—Nausea—Methotrexate—testicular cancer	0.000156	0.000341	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—testicular cancer	0.000155	0.00034	CcSEcCtD
Trametinib—Rash—Epirubicin—testicular cancer	0.000155	0.000339	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—testicular cancer	0.000154	0.000339	CcSEcCtD
Trametinib—Headache—Epirubicin—testicular cancer	0.000154	0.000337	CcSEcCtD
Trametinib—MAP2K2—Immune System—FGFR3—testicular cancer	0.000153	0.000926	CbGpPWpGaD
Trametinib—Dizziness—Doxorubicin—testicular cancer	0.00015	0.000329	CcSEcCtD
Trametinib—Nausea—Epirubicin—testicular cancer	0.000146	0.000319	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways—H2AFZ—testicular cancer	0.000145	0.000875	CbGpPWpGaD
Trametinib—Vomiting—Doxorubicin—testicular cancer	0.000144	0.000316	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways—STK11—testicular cancer	0.000144	0.00087	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FGFR3—testicular cancer	0.000143	0.000866	CbGpPWpGaD
Trametinib—Rash—Doxorubicin—testicular cancer	0.000143	0.000314	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—testicular cancer	0.000143	0.000313	CcSEcCtD
Trametinib—Headache—Doxorubicin—testicular cancer	0.000142	0.000312	CcSEcCtD
Trametinib—MAP2K2—Disease—FGFR3—testicular cancer	0.000141	0.000855	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KIT—testicular cancer	0.000141	0.00085	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—H2AFZ—testicular cancer	0.000135	0.000819	CbGpPWpGaD
Trametinib—Nausea—Doxorubicin—testicular cancer	0.000135	0.000295	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—STK11—testicular cancer	0.000135	0.000814	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KITLG—testicular cancer	0.000133	0.000805	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FGFR3—testicular cancer	0.000132	0.000799	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KIT—testicular cancer	0.000132	0.000795	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KIT—testicular cancer	0.00013	0.000785	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KITLG—testicular cancer	0.000125	0.000753	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KIT—testicular cancer	0.000121	0.000734	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HPGDS—testicular cancer	0.000112	0.000674	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGFR3—testicular cancer	9.9e-05	0.000598	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGFR3—testicular cancer	9.26e-05	0.00056	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—testicular cancer	9.09e-05	0.000549	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—testicular cancer	8.5e-05	0.000514	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—STK11—testicular cancer	8.1e-05	0.00049	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HPGDS—testicular cancer	5.99e-05	0.000362	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—STK11—testicular cancer	4.35e-05	0.000263	CbGpPWpGaD
